2024-514561-20-00CompletedPhase 1
A Phase I study to evaluate the pharmacokinetics, safety and tolerability of multiple oral doses of obefazimod in participants with renal impairment and matched normal kidney function.
Source: EU CTIS (euclinicaltrials.eu) · Last updated 10 Mar 2025
- Status (registry)
- Completed
- Phase (registry)
- Phase 1
- Study type
- Interventional
- Enrollment
- 48 (actual)
- First submitted
- 17 Jun 2024
- Start date
- 9 Sept 2024
- Lead sponsor
- Abivax
- Diseases
- Ulcerative colitis
- EU CT number
- 2024-514561-20-00
What you commit to
- Study type: Interventional · Phase 1
- Participants enrolled: 48
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of EU CTIS (euclinicaltrials.eu). It describes the study design.
Sites (1)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| CRS Clinical Research Services Management GmbH | Kiel | Germany | Completed |
This page is information, not medical advice. Discuss any trial with your doctor.